Trial record 2 of 2 for:    Alzheimer's disease AND RAGE

Evaluation of the Efficacy and Safety of TTP488 in Patients With Mild Alzheimer's Disease

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2014 by TransTech Pharma
Information provided by (Responsible Party):
TransTech Pharma Identifier:
First received: February 25, 2014
Last updated: July 2, 2014
Last verified: July 2014

This is a study to evaluate the efficacy and safety of TTP488 in patients with mild Alzheimer's disease. Patients will receive either TTP488 or placebo with a patient's participation lasting approximately 18 months.

Condition Intervention Phase
Alzheimer's Disease
Drug: TTP488
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine

Resource links provided by NLM:

Further study details as provided by TransTech Pharma:

Primary Outcome Measures:
  • Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) total score [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from Baseline in Magnetic Resonance Imaging (MRI) brain volumetric measures [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Change from Baseline in Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Scan [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Change from Baseline in Neuropsychiatric Inventory (NPI) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Change from Baseline in Mini-Mental State Examination (MMSE) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Change from Baseline in Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS-ADL) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Change from Baseline in Continuous Oral Word Association Task (COWAT) [ Time Frame: 18 month ] [ Designated as safety issue: No ]
  • Change from Baseline in Category Fluency Test (CFT) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Change from Baseline in Resource Utilization in Dementia (RUD) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Change from Baseline in Dementia Quality of Life (DEMQOL) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Change from Baseline in Plasma Amyloid Beta [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Proportion of Responders based on ADAS-cog [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Proportion of Responders based on CDR-SB [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 800
Study Start Date: December 2014
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TTP488 5mg Drug: TTP488
TTP488 5mg administered orally, once daily for 18 months
Placebo Comparator: Placebo Drug: Placebo
Placebo administered orally, once daily for 18 months


Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression of disease
  • Mini Mental State Examination (MMSE) score of 21-26, inclusive
  • Rosen-Modified Hachinski Ischemia Score less than or equal to 4
  • Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD
  • Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least 3 months prior to randomization
  • Caregiver willing to participate and be able to attend clinic visits with patient
  • Ability to ingest oral medications

Exclusion Criteria:

  • Significant neurological or psychiatric disease other than Alzheimer's disease
  • Participants with evidence or history of severe drug allergies (resulting in dyspnea or severe rash).
  • Any contraindications to MRI (e.g., clinically significant claustrophobia, non-removable ferromagnetic implants).
  • Any contraindications to the FDG-PET study (e.g. allergy to any component of the FDG dose) in the mild AD dementia subject cohort undergoing a PET scan.
  • Previous exposure to investigational or non-investigational therapies for Alzheimer's disease that are being investigated for possible disease modification activity
  • History of cancer within the last 5 years. Cutaneous basal cell, squamous cell cancer, resolved by excision, or non-progressive prostate cancer not requiring treatment are allowed.
  • Women of childbearing potential
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02080364

Contact: Aaron H Burstein, PharmD

Sponsors and Collaborators
TransTech Pharma
Study Director: Aaron H Burstein, PharmD TransTech Pharma
  More Information

No publications provided

Responsible Party: TransTech Pharma Identifier: NCT02080364     History of Changes
Other Study ID Numbers: TTP488-301
Study First Received: February 25, 2014
Last Updated: July 2, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by TransTech Pharma:
Alzheimer's disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on September 18, 2014